Home Conferences Contact Us Continuing Education Jobs Weekly News Archives Readership Profile

Monthly News Archives Pharmacy Awards Search Site Search Magazine Archives



26 October 2001 News Update


The Ministry of Health has approved the use of Femara (letrazole) as first-line therapy in post-menopausal women with advanced breast cancer to reduce the risk of the recurrence and prolong survival following surgery.

Previously Femara could only be offered after treatment with tamoxifen had failed.

The move follows major study results released earlier this year that showed Femara is more effective than tamoxifen as first-line treatment therapy for breast cancer in post-menopausal women.

Dr Martine Piccart, chair of the European breast cancer committee and associate professor of oncology at the Free Hospital, Brussels, said the Femara findings are impressive and are likely to have a major impact on established treatment protocols in breast cancer.

Femara, an aromatase inhibitor, acts by inhibiting the aromatase enzyme, blocking the conversion of androgens to oestrogen, thus arresting tumour growth.

Back to welcome page

Back to news archives


Complete this month's questionnaire to qualify for extra Continuing Education credits. Click here
For the answers to last month's quiz click here.


Click here to find out who the winners are for the Pharmacy Today/Zuellig Pharma Pharmacy Awards 2002. Also view and purchase photos of the Awards.


For the leading stories in our latest issue of Pharmacy Today magazine visit our welcome page.


To subscribe to Pharmacy Today, or to purchase The Beauty Manual or The Pharmacy Healthcare Handbook click here.

Consumer Health Information

New Zealand Doctor Online